New data show that routine administration of alvimopan could be a financially viable option for preventing postoperative ileus in patients undergoing radical cystectomy. Hilton et al. performed decision-tree model analysis of healthcare costs and outcome probabilities, and concluded that routine use of alvimopan could reduce costs—assuming that postoperative ileus extends hospital stay by ≥3.5 days and occurs in ≥14% of patients, and alvimopan reduces the risk of postoperative ileus by ≥44%.
ORIGINAL RESEARCH PAPER
Hilton, W. et al. Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. BJU Int. doi:10.1111/j.1464-410X.2012.11499.x
Rights and permissions
About this article
Cite this article
Should all radical cystectomy patients receive alvimopan?. Nat Rev Urol 10, 65 (2013). https://doi.org/10.1038/nrurol.2012.246
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.246